Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Coadministered Ruxolitinib and Artemether-Lumefantrine in Healthy Adults-Reference-Cited by-同舟云学术

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Coadministered Ruxolitinib and Artemether-Lumefantrine in Healthy Adults

Published:2022-01-18 Issue:1 Volume:66 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Chughlay M. Farouk¹,Barnes Karen I.²^ORCID,El Gaaloul Myriam¹,Abla Nada¹,Möhrle Jörg J.¹^ORCID,Griffin Paul³⁴⁵⁶,van Giersbergen Paul⁷,Reuter Stephanie E.⁸,Schultz Hayley B.⁸,Kress Anita⁹,Tapley Peter¹⁰,Webster Rebecca A.³,Wells Timothy¹,McCarthy James S.³⁵,Barber Bridget E.³,Marquart Louise³,Boyle Michelle J.³,Engwerda Christian R.³,Chalon Stephan¹^ORCID

Affiliation:

1. Medicines for Malaria Venture, Geneva, Switzerland

2. Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa

3. QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia

4. Q-Pharm Pty, Ltd., Herston, Queensland, Australia

5. University of Queensland, Brisbane, Queensland, Australia

6. Mater Health Services, South Brisbane, Queensland, Australia

7. Van Giersbergen Consulting, Wuenheim, France

8. UniSA Clinical and Health Sciences, University of South Australia, Adelaide, South Australia, Australia

9. Swiss BioQuant, Reinach, Switzerland

10. TetraQ, Brisbane, Queensland, Australia

Abstract

Despite repeated malaria infection, individuals living in areas where malaria is endemic remain vulnerable to reinfection. The Janus kinase (JAK1/2) inhibitor ruxolitinib could potentially disrupt the parasite-induced dysfunctional immune response when administered with antimalarial therapy.

Funder

Medicines for Malaria Venture

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.01584-21

Reference43 articles.

1. World Trade Report 2020

2. Gamma-Globulin and Acquired Immunity to Human Malaria

3. Functional Antibodies and Protection against Blood-stage Malaria